FULGENT GENETICS, INC. Net Fee Amt
FULGENT GENETICS, INC. (FLGT) had Net Fee Amt of $7.65 thousand as of 2026-05-14, per its S-8 filed 2026-05-14.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-05-14
- 2026-05-14: Net Fee Amt $7.65K.
| Period end | Net Fee Amt |
|---|---|
| 2026-05-14 | $7.65K S-8 · filed 2026-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |